Subscribe

Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy.

Topics Covered:

  • Ruxolitinib cream in pediatric atopic dermatitis

  • Maximum-use study design and outcomes

  • Safety and tolerability in young children (ages 2–11)

  • Expert commentary from JCAD’s Pediatric Dermatology Editor

 

Explore Related Resources:

How to Use Ruxolitinib Cream for Vitiligo

Utilizing Ruxolitinib Cream for Vitiligo

MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS:

Andrew Blauvelt, MD, MBA: Reviewing Upadacitinib Data in Atopic Dermatitis

Dr. Blauvelt discusses the safety and efficacy of upadacitinib in patients with moderate-to-severe atopic dermatitis (AD). In terms of efficacy, he references the Heads Up

PLAY
Zelma Chiesa Fuxench, MD, MSCE: Atopic Dermatitis Patient Selection and Expectations for Ruxolitinib

Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not responded adequately to topical corticosteroids

PLAY
Andrew Mastro, MS, PA-C: Practical Prescribing and Patient Communication for Ruxolitinib in Atopic Dermatitis

Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients

PLAY
Melinda Gooderham, MD, MSc: Best Practices for JAK Inhibition in Atopic Dermatitis

Dr. Gooderham discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK

PLAY
Raj Chovatiya, MD, PhD, MSCI: Advancements in Topical Therapy for Atopic Dermatitis
Raj Chovatiya, MD, PhD, discusses advances in topical atopic dermatitis treatment, including ruxolitinib, rapid itch relief, and treatment of difficult areas.
PLAY
David Seiter, FNP-C: Rapid Relief for Atopic Dermatitis Flares

David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after

PLAY
Christopher Bunick, MD, PhD: Rapid Itch Relief with Upadacitinib vs. Dupilumab in Atopic Dermatitis

Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch

PLAY
George Han, MD, PhD: Advancing Atopic Dermatitis Care: Early Use of Topical JAK Inhibitors
George Han, MD, PhD, discusses the evolving treatment strategies for patients with atopic dermatitis.
PLAY
Kara Mudd DMSc, PA-C: Use of Ruxolitinib in Pediatric Patients with Atopic Dermatitis
Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion
PLAY
Mona Shahriari, MD: Removal of Black Box Warnings Change Considerations for Hormonal Therapy in Atopic Dermatitis

Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment

PLAY
Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

PLAY
Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for

PLAY